What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.

How has cancer care changed from the initial outbreak of the COVID-19 pandemic? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston, shares how he has been treating his patients during the COVID-19 pandemic.

Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter season.

The healthcare disparity crisis in the breast cancer field has prevented the benefits of therapeutic advancements from being equally distributed throughout all populations. What can we do to overcome this obstacle? Dr. Mariana Chavez MacGregor, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the disparities she's encountered in breast cancer care.

Healthcare professionals have found that zip code is a better indicator of health for many patients rather than cholesterol or genetics, highlighting a significant disparity in the field of medicine. What can we do to overcome this obstacle? Dr. Christopher Lathan, Associate Medical Director of the Dana Farber Cancer Institute Network, explains how we can better connect with our patients to improve their care.

Oftentimes, a patient’s zip code is a better indicator of health than blood pressure or genetics, highlighting a significant disparity among communities. How are barriers such as systemic racism contributing to this disparity, and what can we do to change that? Dr. Jacob Sands is joined by Dr. Christopher Lathan to discuss medical disparities as a result of systemic racism.

After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medical Oncology at Emory University School of Medicine, joins Dr. Jacob Sands to talk about long-awaited developments in small cell lung cancer.

As the number of cancer survivors continues to grow due to treatment advances, so too do the long-term impacts like cardiovascular complications. That’s why the field of cardio-oncology has emerged, and to learn more, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

Throughout this global pandemic, radiation oncologists are faced with the challenge of finding ways to continue administering the necessary cancer treatments while limiting their patients’ risk of exposure to COVID-19. Dr. Anthony Dragun from the MD Anderson Cancer Center is here to explain how that can be done and why these new approaches should be embraced even after the COVID-19 pandemic is over.

Published April 27, 2020

Due to the many challenges and complications that are now facing oncologists and their patients requiring lung cancer treatment, lung cancer care is changing in many ways to help minimize a patient’s risk of exposure, as Dr. Jonathan Riess from the UC Davis Medical Center explains.

Published April 24, 2020